Genomes and Genes
Don M Benson
Affiliation: The Ohio State University
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myelomaDon M Benson
Division of Hematology, The Ohio State University, Columbus, OH 43210 1240, USA
Blood 120:4324-33. 2012..These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396...
- A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cellsLi Lin
Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, Ohio 43205, USA
Mol Cancer 9:217. 2010..A novel small molecular STAT3 inhibitor, FLLL32 was specifically designed from dietary agent, curcumin to inhibit constitutive STAT3 signaling in multiple myeloma, glioblastoma, liver cancer, and colorectal cancer cells...
- Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myelomaDon M Benson
Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA
Leuk Lymphoma 51:243-51. 2010..Our data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM planned for subsequent HDC/SCT and optimal sequencing of therapies...
- IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effectDon M Benson
Division of Hematology, The Ohio State University, Columbus, OH, USA
Blood 118:6387-91. 2011..These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM...
- High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myelomaDon M Benson
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling Loving Hall, Columbus, OH 43210, USA
Leuk Res 31:1069-75. 2007..BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM...
- Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agentsSherry Mori
Department of Pharmacy, The Ohio State University Comprehensive Cancer Center, OH, USA
Hematol Oncol 30:156-62. 2012..These findings suggest potentially novel roles for sFLC in patients with MM with an intact M protein receiving novel agent-based induction strategies followed by HDC/SCT...
- Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphomaMehdi Hamadani
Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
Leuk Lymphoma 49:1893-8. 2008..Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates...
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibodyDon M Benson
Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
Blood 116:2286-94. 2010..A phase 2 clinical trial of CT-011 in combination with lenalidomide for patients with MM should be considered...
- High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphomaMehdi Hamadani
Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Eur J Haematol 81:425-31. 2008..At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively...
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignanciesMehdi Hamadani
Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
Biol Blood Marrow Transplant 15:1422-30. 2009....
- The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activityMatthew A Bill
Department of Surgery, Arthur G, James Cancer Hospital and Richard J, Solove Research Institute, The Ohio State University, 410 W, 10th Ave, Columbus, OH 43210, USA
Mol Cancer 9:165. 2010..We hypothesized this lead compound would specifically inhibit the STAT3 signaling pathway to induce apoptosis in melanoma cells...
- A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cellsLi Lin
Department of Pediatrics, Center for Childhood Cancer, The Research Institute at Nationwide Children s Hospital, Columbus, OH 43205, USA
Int J Cancer 130:1459-69. 2012..Furthermore, LLL12 significantly blocked tumor growth of MM cells in mouse model. Our results indicate that LLL12 blocks constitutive STAT3 and IL-6 induced STAT3 signaling and may be a potential therapeutic agent for MM...
- MicroRNAs activate natural killer cells through Toll-like receptor signalingShun He
Comprehensive Cancer Center
Blood 121:4663-71. 2013..This may be important in the normal host defense against infection and/or malignant transformation...
- Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokinesMatthew A Bill
Department of Internal Medicine, Division of Hematology and Oncology, 302B Comprehensive Cancer Center, Columbus, OH 43210, USA
Mol Cancer Ther 8:2726-35. 2009..These data show that although curcumin can induce apoptosis of melanoma cells, it can also adversely affect the responsiveness of immune effector cells to clinically relevant cytokines that possess antitumor properties...
- Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani
Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
Biol Blood Marrow Transplant 15:547-53. 2009..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy...
- Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinCraig C Hofmeister
The Ohio State University, Columbus, OH 43210, USA
J Clin Oncol 29:3427-34. 2011..The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM...
- A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancerManisha H Shah
Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, USA
Clin Cancer Res 12:3993-6. 2006..To determine the safety, toxicity, and immune modulation of this combination of cytokines in vivo, we conducted a first-in-man phase I study...
- Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approachCarlos Arce-Lara
Department of Internal Medicine, Division of Hematology Oncology, Ohio State University, Columbus, Ohio 43210 1280, USA
Urology 69:1209.e5-7. 2007..We describe the clinical presentation and diagnostic and therapeutic approach to these cases, highlighting the successful preoperative use of imatinib mesylate (Gleevec) followed by prostatectomy...
- Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myelomaNeil C Dunavin
Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
Leuk Lymphoma 54:1658-64. 2013..037). No superiority of one agent was seen. In summary, early or late ASCT is a viable option for patients with MM receiving induction treatment with novel targeted therapies...
- The role of natural killer cells in immunity against multiple myelomaJames Godfrey
The Ohio State University College of Medicine, Columbus, OH, USA
Leuk Lymphoma 53:1666-76. 2012..The present review summarizes the current understanding of the NK cell versus MM effect and characterizes therapeutic interventions that exert anti-MM efficacy via NK cell function against the disease...
- NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and humanJianhua Yu
Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, USA
J Clin Invest 121:1456-70. 2011..Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia...
- VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrineEric V Yang
Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Medical Center, Columbus, OH 43210, USA
Brain Behav Immun 22:318-23. 2008..The data suggest that the ability of NE to regulate the expression of VEGF is not limited to solid epithelial tumors and suggests a possible regulatory role of catecholamine stress hormones in MM progression...
- Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assaySri Vidya Kondadasula
Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
Cancer Immunol Immunother 57:1137-49. 2008..These studies reveal an effective method to detect ERK activation in immune cells and demonstrate that IL-2 activates ERK in a subset of NK cells and monocytes but not T cells...
- Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cellsDon M Benson
Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210 1240, USA
Blood 113:2706-14. 2009..The effect results at least in part via enhanced MAPK-mediated modulation of p27 and CDK4. Collectively the data reveal a novel mechanism by which SCF enhances cellular proliferation in combination with IL-2/15 in primary human NK cells...
- CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibodyFarrukh T Awan
Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Blood 115:1204-13. 2010..These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies...
- Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma developmentFlavia Pichiorri
Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
Cancer Cell 18:367-81. 2010..The results suggest that these miRNAs are positive regulators of p53 and that their downregulation plays a key role in MM development...
- Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cellsBrian Becknell
Medical Scientist Program, Department of Internal Medicine, College of Medicine and Public Health, The Ohio State University, Columbus, OH 43210, USA
Blood 109:2481-7. 2007..Thus, Hlx expression in activated NK cells temporally controls and limits the monokine-induced production of IFN-gamma, in part through the targeted depletion of STAT4...
- CD94 defines phenotypically and functionally distinct mouse NK cell subsetsJianhua Yu
Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
J Immunol 183:4968-74. 2009..Collectively, our data suggest that CD94 is an Ag that can be used to identify functionally distinct NK cell subsets in mice and could also be relevant to late-stage mouse NK cell development...
- Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cellsJianhua Yu
Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University College of Medicine and School of Public Health, Columbus, Ohio 43210, USA
Immunity 24:575-90. 2006..Collectively, our data suggest that pro- and antiinflammatory cytokine signaling reciprocally antagonize each other in an effort to prevail in the regulation of NK cell IFN-gamma production...
- The effect of statin use at the time of autologous transplant on response and survival in multiple myelomaMehdi Hamadani
Biol Blood Marrow Transplant 14:351-2. 2008
- A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphomaKhuda D Khan
American Health Network Oncology Hematology, Indianapolis, Indiana, USA
Clin Cancer Res 12:7046-53. 2006..Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted...
- Dramatic response to single-agent rituximab in a patient with intravascular lymphomaNandagopal Vrindavanam
Am J Hematol 82:1120-1. 2007
- Thalidomide-induced fulminant hepatic failureMehdi Hamadani
Mayo Clin Proc 82:638. 2007